- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pfizer Gains Access to 23andMe's Genetic Mine
23andMe is betting its growing troves of genetic data will prove essential to drug companies, medical researchers, and even health and wellness companies.
23andMe Inc., the genetic-testing startup backed by Google Inc. (GOOG), is sharing DNA data on about 650,000 individuals with Pfizer Inc. (PFE), to help find new targets to treat disease and to design clinical trials.
The collaboration with Pfizer is the broadest announced so far in 23andMe’s ambitious plan to become a repository for humanity’s genetic makeup, and to turn data gathered from $99 saliva tests sold to consumers into multimillion-dollar deals with drugmakers.
The agreement unveiled today gives the U.S.’s largest drugmaker access to anonymous, aggregated information from consumers who bought 23andMe’s test over the past seven years to learn about their own genetic histories. It includes only people who agreed to let their data be used in research. Pfizer and 23andMe declined to give the deal’s value.
Reported on Bloomberg: http://bloom.bg/1xhimt3
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
